文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

中国衢州 2022 年 3 月至 5 月两次疫情期间 COVID-19 疫苗对 SARS-CoV-2 奥密克戎变异株的有效性。

Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.

机构信息

Department of Immunity, Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang Province, China.

School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.

出版信息

Hum Vaccin Immunother. 2023 Dec 31;19(1):2163813. doi: 10.1080/21645515.2022.2163813. Epub 2023 Jan 27.


DOI:10.1080/21645515.2022.2163813
PMID:36704960
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10012893/
Abstract

Limited data are available on the effectiveness of COVID-19 vaccines used in China in real-world outbreaks - especially against Omicron variants in vaccinated individuals. Two outbreaks of SARS-CoV-2 Omicron variants - the first involving the sub-lineage BA.2 and the second the BA.1 variant - occurred in Quzhou. Infected people and their close contacts were divided according to vaccination status: unvaccinated, partially vaccinated, fully vaccinated, and boosted. The Cox proportional-hazard regression model was used to estimate the evolving hazard for vaccinated individuals after their first immunization. 138 people had been infected with the SARS-CoV-2 Omicron BA.2 variant and 13 with the BA.1 variant. Of the 151 infections, 99.34% (150/151) were mild or asymptomatic and 90.07% (136/151) were vaccine breakthrough cases. The total vaccine effectiveness (VE) of partial, full, and booster vaccinations during the two outbreaks was 47.4% (95%CI: 0-93.1%), 28.9% (95%CI: 0-60.2%), and 27.5% (95%CI: 0-58.3%). The VE of booster vaccination against the Omicron BA.1 variant was higher than that for the BA.2 variant. The cumulative hazard began to increase 220 days after the first immunization. The transmissibility of the Omicron BA.2 variant as for BA.1 did not increase in vaccinated individuals; booster vaccination after a primary course substantially increased protection. Our study found that the SARS-CoV-2 Omicron variant caused less severe illness and that the VE of boosters against the Omicron variant was less than 30%. Timely administration of the booster dose was important, especially for individuals aged over 80 years old.

摘要

在中国的真实世界疫情中,关于已使用的 COVID-19 疫苗的有效性数据有限 - 特别是针对接种疫苗个体的奥密克戎变异株。在衢州发生了两起 SARS-CoV-2 奥密克戎变异株疫情 - 第一次涉及亚谱系 BA.2,第二次涉及 BA.1 变异株。感染者及其密切接触者根据接种状态进行了划分:未接种、部分接种、完全接种和加强接种。使用 Cox 比例风险回归模型来估计接种者在首次免疫后的危险率变化。有 138 人感染了 SARS-CoV-2 奥密克戎 BA.2 变异株,13 人感染了 BA.1 变异株。在 151 例感染中,99.34%(150/151)为轻症或无症状,90.07%(136/151)为疫苗突破性病例。在两次疫情中,部分、完全和加强接种的总疫苗效力(VE)分别为 47.4%(95%CI:0-93.1%)、28.9%(95%CI:0-60.2%)和 27.5%(95%CI:0-58.3%)。加强接种对奥密克戎 BA.1 变异株的 VE 高于 BA.2 变异株。首次免疫后 220 天,累积危险率开始增加。接种疫苗者中奥密克戎 BA.2 变异株的传染性与 BA.1 相同,初级疗程后的加强接种大大增加了保护。我们的研究发现,SARS-CoV-2 奥密克戎变异株引起的疾病较轻,而针对奥密克戎变异株的加强针 VE 低于 30%。及时接种加强针很重要,特别是对于 80 岁以上的个体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d361/10012893/ac77992d8090/KHVI_A_2163813_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d361/10012893/f3380859b353/KHVI_A_2163813_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d361/10012893/ac77992d8090/KHVI_A_2163813_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d361/10012893/f3380859b353/KHVI_A_2163813_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d361/10012893/ac77992d8090/KHVI_A_2163813_F0002_OC.jpg

相似文献

[1]
Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.

Hum Vaccin Immunother. 2023-12-31

[2]
Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study.

Hum Vaccin Immunother. 2023-12-31

[3]
Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.

Respir Res. 2023-10-12

[4]
Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.

Front Immunol. 2023

[5]
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.

Lancet Infect Dis. 2023-4

[6]
The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China.

Front Immunol. 2024

[7]
Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China.

Front Immunol. 2023

[8]
Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.

Vaccine. 2023-3-24

[9]
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.

Front Immunol. 2022

[10]
BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.

Lancet Child Adolesc Health. 2023-7

引用本文的文献

[1]
Vaccination, infection, and hybrid immunity: determinants of SARS-CoV-2 IgG antibody levels and protection in Quzhou, China.

Front Immunol. 2025-7-28

[2]
Impact of Vaccination and Public Health Measures on the Severity of SARS-CoV-2 Omicron Infections in China: A Systematic Review and Meta-Regression Analysis.

Vaccines (Basel). 2025-7-12

[3]
Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity.

Heliyon. 2024-7-17

[4]
SARS-CoV-2 Infection, Hospitalization, and Associated Factors Among People Living With HIV in Southeastern China From December 2022 to February 2023: Cross-Sectional Survey.

JMIR Public Health Surveill. 2024-4-17

本文引用的文献

[1]
[Epidemiological characteristics of two local COVID-19 outbreaks caused by 2019-nCoV Omicron variant in Guangzhou, China].

Zhonghua Liu Xing Bing Xue Za Zhi. 2022-11-10

[2]
The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection.

Vaccines (Basel). 2022-10-11

[3]
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.

Lancet Infect Dis. 2023-3

[4]
Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.

BMC Med. 2022-10-20

[5]
Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants.

J Infect Dis. 2023-2-1

[6]
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.

Lancet Infect Dis. 2022-10

[7]
Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China.

Hum Vaccin Immunother. 2022-11-30

[8]
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England.

Lancet Infect Dis. 2022-7

[9]
Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile.

Nat Med. 2022-7

[10]
Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.

Vaccine. 2022-5-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索